Moneycontrol PRO
HomeNewsGlenmarkpharma

Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

Jump to
  • Buy Ranbaxy on decline: Jain

    Buy Ranbaxy on decline, says Rajesh Jain, Independent Market Strategist.

  • Buy Glenmark Pharma above Rs 320: Mohindar

    Buy Glenmark Pharma above Rs 320, says Rahul Mohindar of Viratechindia.

  • Kunal Bothra's view on Glenmark Pharma

    If Glenmark Pharma closes above Rs 305 then we can go long on this stock, says Kunal Bothra of LKP.

  • Prashastha Seth view on Glenmark Pharma

    I wouldn’t expect Glenmark Pharma to perform better from here on in the back of the out licensing deal, says Prashastha Seth, Senior VP IIFL Private Wealth, IIFL.

  • Glenmark Pharma a top pick: Diwan

    Glenmark Pharma a top pick, says Prakash Diwan, Head-Institutional Business, Networth Stock Broking.

  • IIFL Capital view on Glenmark Pharma

    Glenmark’s domestic business is doing pretty well, growing reasonably well, good margins and cash generating business, says Bino Pathiparampil, Vice President of IIFL Capital.

  • Glenmark Pharma can test Rs 310-315: Mitesh Thacker

    Glenmark Pharma can test Rs 310-315, says Mitesh Thacker, Technical Analyst, miteshthacker.com.

  • Chakraborty's view on Jammu and Kashmir Bank, Glenmark

    Abhijit Chakraborty, Sr. VP - Institutional Equity, Fortune Financial view on Jammu and Kashmir Bank and Glenmark Pharma.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347